<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) is an <z:e sem="disease" ids="C0004364" disease_type="Disease or Syndrome" abbrv="">autoimmune disorder</z:e> presenting with tissue injury in various organs related to large- or small-vessel <z:mp ids='MP_0005048'>thrombosis</z:mp> associated with antiphospholipid and antiprotein/<z:chebi fb="0" ids="16247">phospholipid</z:chebi> complex antibodies </plain></SENT>
<SENT sid="1" pm="."><plain>Although the pathophysiology, diagnosis, and clinical scenario may seem clear and straightforward, a more detailed examination reveals a more complex and uncertain picture related to the management of APS </plain></SENT>
<SENT sid="2" pm="."><plain>This article reviews the current situation relating to APS therapy by evaluating the different clinical features of the syndrome ranging from <z:mp ids='MP_0005048'>thrombosis</z:mp> to <z:e sem="disease" ids="C0032962" disease_type="Disease or Syndrome" abbrv="">pregnancy complications</z:e> together with new strategies and pharmacological approaches </plain></SENT>
</text></document>